Arthritis & Rheumatology最新文献

筛选
英文 中文
The secretome of UC-MSC reprogrammed to a glycolytic metabolism promotes Treg generation and naive CD4 T cells stability in PBMC from rheumatoid arthritis patients. UC-MSC的分泌组被重编程为糖酵解代谢,促进类风湿关节炎患者PBMC中Treg的生成和初始CD4 T细胞的稳定性。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 DOI: 10.1002/art.70382
Noymar Luque-Campos, Carolina Pradenas, Eliana Lara-Barba, Yesenia Flores-Elías, Bruno Torres-Gonzalez, Francisca Troncoso, Yeimi Herrera-Luna, Felipe A Bustamante-Barrientos, Constanza Aros-Valdivia, María Jesus Araya-Sapag, Cesar Merino-Flores, Bianca Bustamante, Guilhem Graveron, Jonathan Morales-Reyes, Alexander Ortloff, Pablo Cruz, Alvaro A Elorza, Andrea Matamoros, Karina Oyarce, Claudia Altamirano, Ana María Vega-Letter, Francisco Espinoza, Catalina Infante, Mauricio Quezada-Diez, María Paz Hernandez-Cáceres, Rafael Contreras-Lopez, Yves-Marie Pers, Yessia Hidalgo-Fadic, Roberto Elizondo-Vega, Farida Djouad, Patricia Luz-Crawford
{"title":"The secretome of UC-MSC reprogrammed to a glycolytic metabolism promotes Treg generation and naive CD4 T cells stability in PBMC from rheumatoid arthritis patients.","authors":"Noymar Luque-Campos, Carolina Pradenas, Eliana Lara-Barba, Yesenia Flores-Elías, Bruno Torres-Gonzalez, Francisca Troncoso, Yeimi Herrera-Luna, Felipe A Bustamante-Barrientos, Constanza Aros-Valdivia, María Jesus Araya-Sapag, Cesar Merino-Flores, Bianca Bustamante, Guilhem Graveron, Jonathan Morales-Reyes, Alexander Ortloff, Pablo Cruz, Alvaro A Elorza, Andrea Matamoros, Karina Oyarce, Claudia Altamirano, Ana María Vega-Letter, Francisco Espinoza, Catalina Infante, Mauricio Quezada-Diez, María Paz Hernandez-Cáceres, Rafael Contreras-Lopez, Yves-Marie Pers, Yessia Hidalgo-Fadic, Roberto Elizondo-Vega, Farida Djouad, Patricia Luz-Crawford","doi":"10.1002/art.70382","DOIUrl":"https://doi.org/10.1002/art.70382","url":null,"abstract":"<p><strong>Objective: </strong>Rheumatoid arthritis (RA) is characterized by persistent inflammation and dysregulated T cell responses. Mesenchymal stromal cells (MSCs) have immunomodulatory properties, but their clinical efficacy remains variable. We investigated whether metabolic reprogramming of umbilical cord-derived MSCs (UC-MSCs) toward glycolysis enhances their immunoregulatory function and the underlying mechanisms.</p><p><strong>Methods: </strong>UC-MSCs were reprogrammed toward glycolysis by pharmacologic inhibition of oxidative phosphorylation using oligomycin. Their immunomodulatory capacity was assessed in coculture with activated peripheral blood mononuclear cells (PBMCs) from 21 RA patients under direct-contact and conditioned-medium conditions. T cell proliferation, phenotype, and cell cycle were analyzed by flow cytometry. Anti-inflammatory effects were evaluated in a delayed-type hypersensitivity (DTH) murine model, and the contribution of the UC-MSC secretome and its protein fraction was investigated.</p><p><strong>Results: </strong>Glycolysis-reprogrammed UC-MSCs exhibited enhanced immunosuppressive activity compared with unmodified UC-MSCs, suppressing proinflammatory T cell responses, promoting Treg expansion, and preserving CD4<sup>+</sup>CD45RA<sup>+</sup> naïve T cells. These effects were associated with T cell cycle arrest in G0. Conditioned-medium experiments showed that these effects were largely mediated by the MSC secretome, increasing Treg frequency from 16.5% to 30.2% and enriching the CD4<sup>+</sup>CD45RA<sup>+</sup> naïve T-cell compartment from 9.7% to 29.1%, with the protein fraction accounting for most of this immunomodulatory activity. In vivo, the >3 kDa protein-enriched fraction attenuated DTH-associated inflammation and promoted an anti-inflammatory immune response.</p><p><strong>Conclusion: </strong>Metabolic reprogramming of UC-MSCs toward glycolysis enhances their immunomodulatory capacity through secretome-dependent mechanisms, primarily mediated by proteins within the >3 kDa fraction, supporting metabolism-based and cell-free strategies for MSC-based therapy in RA.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Risks of Mortality and Fractures in Patients With Osteoarthritis Initiating Tramadol Versus Other Opioids. 曲马多与其他阿片类药物对骨关节炎患者死亡率和骨折风险的比较
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 DOI: 10.1002/art.70383
Sushama Kattinakere Sreedhara, Sungho Bea, Krista F Huybrechts, Nazleen F Khan, Jeffrey N Katz, Shruti Belitkar, Angela Y Tong, Katsiaryna Bykov
{"title":"Comparative Risks of Mortality and Fractures in Patients With Osteoarthritis Initiating Tramadol Versus Other Opioids.","authors":"Sushama Kattinakere Sreedhara, Sungho Bea, Krista F Huybrechts, Nazleen F Khan, Jeffrey N Katz, Shruti Belitkar, Angela Y Tong, Katsiaryna Bykov","doi":"10.1002/art.70383","DOIUrl":"10.1002/art.70383","url":null,"abstract":"<p><strong>Objective: </strong>Tramadol is commonly used to manage pain in patients with osteoarthritis, but its comparative safety in this population remains largely unknown. The study aimed to evaluate the risks of all-cause mortality and fracture among patients with osteoarthritis initiating tramadol versus other prescribed opioids.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using Optum Clinformatics Data Mart (2005-2021). Adults aged ≥50 years with osteoarthritis initiating tramadol, codeine, hydrocodone, or oxycodone were included. Outcomes were all-cause mortality and fractures. Propensity score weighting balanced baseline characteristics, and weighted Cox proportional hazards models estimated adjusted hazard ratios (HRs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Among 1,057,635 patients (mean age 69.1 years; 62.5% female), 294,760 initiated tramadol, 97,048 codeine, 474,733 hydrocodone, and 191,094 oxycodone. During follow-up, 9,988 deaths and 10,455 fractures occurred. Tramadol showed similar mortality risk to codeine (HR 0.93, 95% CI 0.73-1.19) but lower risk compared with hydrocodone (HR 0.81, 95% CI 0.70-0.93) and oxycodone (HR 0.40, 95% CI 0.34-0.47). Fracture risk was comparable to codeine (HR 1.10, 95% CI 0.96-1.25) and lower than hydrocodone (HR 0.91, 95% CI 0.83-0.98) and oxycodone (HR 0.83, 95% CI 0.75-0.93).</p><p><strong>Conclusion: </strong>In adults aged 50 years or older with osteoarthritis initiating an opioid, tramadol initiation was associated with lower risks of death and fractures compared with hydrocodone and oxycodone, and similar risks compared with codeine. These findings suggest that tramadol may be a comparatively favorable option when opioid therapy is necessary, although its longer-term comparative safety remains uncertain.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis 肺超声对类风湿关节炎患者肺间质性异常影像学进展的检测
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-05-03 DOI: 10.1002/art.70161
Marie Vermant MD, PhD, Valerie Van Ballaer MD, Joseph Jacob MD, PhD, Tine Follet MD, Ryoko Egashira MD, PhD, Kenny Anseele MD, Heleen Cypers MD, Laurens J. De Sadeleer MD, PhD, Nico De Crem MD, Tinne Goos MD, PhD, Barbara Neerinckx MD, PhD, Veerle Taelman MD, Nathalie Veyt MD, Alexandros Kalkanis MD, PhD, Patrick Verschueren MD, PhD, Wim A. Wuyts MD, PhD
{"title":"Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis","authors":"Marie Vermant MD, PhD,&nbsp;Valerie Van Ballaer MD,&nbsp;Joseph Jacob MD, PhD,&nbsp;Tine Follet MD,&nbsp;Ryoko Egashira MD, PhD,&nbsp;Kenny Anseele MD,&nbsp;Heleen Cypers MD,&nbsp;Laurens J. De Sadeleer MD, PhD,&nbsp;Nico De Crem MD,&nbsp;Tinne Goos MD, PhD,&nbsp;Barbara Neerinckx MD, PhD,&nbsp;Veerle Taelman MD,&nbsp;Nathalie Veyt MD,&nbsp;Alexandros Kalkanis MD, PhD,&nbsp;Patrick Verschueren MD, PhD,&nbsp;Wim A. Wuyts MD, PhD","doi":"10.1002/art.70161","DOIUrl":"10.1002/art.70161","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Interstitial lung disease (ILD) is an important extra-articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung abnormalities (ILAs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective pilot study, patients with RA underwent high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), symptom assessment, and LUS at baseline and 12 to 18 months later. B-lines were quantified using a 72-zone protocol. Radiologic changes across longitudinal HRCTs were scored on a five-point Likert scale by blinded thoracic radiologists. Six multivariable logistic regression models were built to predict HRCT progression using combinations of LUS parameters, PFTs, symptoms, and clinical characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty-one patients completed the follow-up HRCT, and per-protocol LUS was performed in 95% (77/81). Radiologic progression was observed in 31% (25/81). An increase in B-lines was significantly associated with radiologic progression (<i>P</i> = 0.018), and a linear trend was confirmed (<i>P</i> = 0.026). In multivariable analysis, both baseline B-lines (<i>P</i> = 0.029) and the change in B-lines over time (<i>P</i> = 0.012) significantly predicted progression (area under the curve [AUC] 0.78, 95% confidence interval [CI] 0.64–0.92). When combining LUS and change in diffusing capacity for carbon monoxide (AUC 0.82, 95% CI 0.70–0.94), the model fit remained similar and outperformed symptom scores (AUC 0.58, 95% CI 0.40–0.75, <i>P</i> = 0.020) and PFTs (AUC 0.59, 95% CI 0.44–0.74, <i>P</i> = 0.022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>LUS may be a useful, radiation-free tool to monitor and predict radiologic progression of ILAs in RA. These findings support further research into integrating LUS into longitudinal RA-ILD assessment, particularly as part of a multimodal approach.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2221-2231"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70161","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147599210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linking T Cell States to T Cell Receptors in Systemic Lupus Erythematosus SLE中T细胞状态与tcr的联系。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-06-20 DOI: 10.1002/art.70254
Zandra E. Walton MD, PhD, Deepak A. Rao MD, PhD
{"title":"Linking T Cell States to T Cell Receptors in Systemic Lupus Erythematosus","authors":"Zandra E. Walton MD, PhD,&nbsp;Deepak A. Rao MD, PhD","doi":"10.1002/art.70254","DOIUrl":"10.1002/art.70254","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2186-2188"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148248500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis 专家观点:系统性硬化症进行性肺纤维化的定义和管理。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-06-20 DOI: 10.1002/art.70237
Devis Benfaremo MD, PhD, Dinesh Khanna MD, MSc, Corrado Campochiaro MD, Vincent Cottin MD, Fabrizio Luppi MD, PhD, Marco Matucci-Cerinic MD, PhD, Gianluca Moroncini MD, PhD, Yannick Allanore MD, PhD
{"title":"Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis","authors":"Devis Benfaremo MD, PhD,&nbsp;Dinesh Khanna MD, MSc,&nbsp;Corrado Campochiaro MD,&nbsp;Vincent Cottin MD,&nbsp;Fabrizio Luppi MD, PhD,&nbsp;Marco Matucci-Cerinic MD, PhD,&nbsp;Gianluca Moroncini MD, PhD,&nbsp;Yannick Allanore MD, PhD","doi":"10.1002/art.70237","DOIUrl":"10.1002/art.70237","url":null,"abstract":"<p>Systemic sclerosis–associated interstitial lung disease (SSc-ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three-quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF). Identifying patients at risk for progression remains a key clinical challenge. Routine screening with high-resolution computed tomography at diagnosis and regular pulmonary function test monitoring are essential for early detection and timely management. Recent efforts have sought to harmonize the definition of PPF across fibrosing ILDs, recognizing shared clinical and pathophysiological mechanisms beyond idiopathic pulmonary fibrosis. Approximately 20% to 30% of patients with SSc-ILD develop PPF, yet reliable predictors of progression remain elusive. Advances in imaging, functional assessment, and molecular biomarkers hold promise for improving risk stratification. Therapeutic approaches have evolved from conventional immunosuppression toward combination and antifibrotic strategies. Mycophenolate mofetil remains the preferred first-line therapy, whereas nintedanib is the only antifibrotic agent approved for both SSc-ILD and PPF, having demonstrated efficacy in slowing lung function decline. Combination therapy, particularly mycophenolate mofetil with nintedanib or biologics such as rituximab and tocilizumab, is gaining traction in clinical practice despite limited comparative data. Emerging antifibrotic and anti-inflammatory agents offer new therapeutic prospects. This review summarizes current understanding of PPF in SSc-ILD, focusing on its evolving definition, prognostic determinants, and treatment landscape, and highlights unmet needs for personalized, evidence-based management.</p><p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2189-2202"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148136048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study 低级别蛋白尿不能预测狼疮性肾炎的预后:一项纵向队列研究
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-02-25 DOI: 10.1002/art.70009
Yiwei Shen MS, Jingyi Peng BS, Dai Dai PhD, Min Dai MD, PhD, Ting Li MD, PhD, Sheng Chen MD, PhD, Shuang Ye MD, PhD, Nan Shen MD, PhD, Huihua Ding MD
{"title":"Low-Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study","authors":"Yiwei Shen MS,&nbsp;Jingyi Peng BS,&nbsp;Dai Dai PhD,&nbsp;Min Dai MD, PhD,&nbsp;Ting Li MD, PhD,&nbsp;Sheng Chen MD, PhD,&nbsp;Shuang Ye MD, PhD,&nbsp;Nan Shen MD, PhD,&nbsp;Huihua Ding MD","doi":"10.1002/art.70009","DOIUrl":"10.1002/art.70009","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the clinical characteristics, renal pathology treatment responses, and renal outcomes of patients with lupus nephritis (LN) with different levels of baseline proteinuria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 239 patients with biopsy-proven LN were stratified by baseline 24-h urine protein (UPro) levels (&lt;1 g/24 h vs ≥1 g/24 h) and disease onset status (incident vs relapsing). Renal treatment responses were measured by overall renal response, complete response, and primary efficacy renal response at weeks 26 and 52. Cox proportional hazards regression and Kaplan-Meier analyses were used to assess predictors of time to first 30% and 40% estimated glomerular filtration rate (eGFR) decline by 156 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 239 patients with LN, 42 (17.6%) had UPro &lt;1 g/24 h, and 197 (82.4%) had UPro ≥1 g/24 h; 122 (51.0%) had incident LN and 117 (49.0%) had relapsing LN. The UPro &lt;1 group had a lower incidence of urinary sediments, a higher frequency of class V, and a lower renal pathology activity index but similar chronicity index compared with the UPro ≥1 group. Both groups exhibited similar overall renal response rates at weeks 26 and 52. Patients with low-grade proteinuria had equivalent risk probabilities for experiencing a 30% or 40% decline in eGFR over 156 weeks compared with those with high-grade proteinuria. Glomerulosclerosis independently predicted long-term renal deterioration in relapsing but not incident LN.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Low-grade proteinuria (UPro &lt;1g/24h) does not confer better renal outcomes or treatment response in LN. Glomerulosclerosis predicts renal function decline in relapsing LN. These results underscore the importance of early biopsy, personalized therapy, and close monitoring, supported by noninvasive biomarkers for risk assessment.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2305-2316"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145611243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis 巨细胞动脉炎随机对照试验中的18f -氟脱氧葡萄糖正电子发射断层成像评估
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-05-05 DOI: 10.1002/art.70166
Kaitlin A. Quinn MD, MHS, Sovira Tan PhD, Pauline Verdijk PhD, Linda Okonkwo MD, MBA, Maxime Samson MD, PhD, Daniel Blockmans MD, PhD, Jean-Paul Makhzoum MD, MSc, Maria C. Cid MD, Joerg Henes MD, PhD, Verena Schönau MD, Mark A. Ahlman MD, Peter C. Grayson MD, MSc
{"title":"18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis","authors":"Kaitlin A. Quinn MD, MHS,&nbsp;Sovira Tan PhD,&nbsp;Pauline Verdijk PhD,&nbsp;Linda Okonkwo MD, MBA,&nbsp;Maxime Samson MD, PhD,&nbsp;Daniel Blockmans MD, PhD,&nbsp;Jean-Paul Makhzoum MD, MSc,&nbsp;Maria C. Cid MD,&nbsp;Joerg Henes MD, PhD,&nbsp;Verena Schönau MD,&nbsp;Mark A. Ahlman MD,&nbsp;Peter C. Grayson MD, MSc","doi":"10.1002/art.70166","DOIUrl":"10.1002/art.70166","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To compare fluorodeoxyglucose (FDG)–positron emission tomography (PET) imaging to clinical- and laboratory-based assessments of disease activity in a randomized controlled trial (RCT) in giant cell arteritis (GCA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with new-onset or relapsing GCA were randomized to guselkumab or placebo plus tapered glucocorticoids in an international, multicenter RCT. FDG-PET was performed at the baseline visit before randomization and repeated at disease flare or the week-52 visit (clinical remission off glucocorticoids). FDG-PET scans were interpreted as active or inactive by two readers, and the PET Vascular Activity Score was calculated to quantify arterial FDG uptake. FDG-PET findings were compared to clinical assessment, acute phase reactants, and glucocorticoid use at each visit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Baseline FDG-PET scans were interpreted as active vasculitis in 28 (55%) of 51 patients. FDG-PET activity at enrollment was not associated with clinical symptoms, acute phase reactants, or risk of flare. Younger age (70 vs 76 years; <i>P</i> = 0.03) and female sex (89% vs 48%, <i>P</i> &lt; 0.01) were significantly associated with increased FDG-PET activity. There were no differences in prior glucocorticoid dose (median 780 mg) or duration (median 23 days) between patients with baseline active versus inactive FDG-PET scans. FDG-PET scans were active in 17 of 21 (81%) patients during clinical flare and in 14 of 20 (70%) patients at week 52. Subsets of patients had persistently active (n = 21) or inactive (n = 9) PET scans at all time points, independent of clinical assessment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vascular FDG-PET activity may be discordant with clinical assessment, particularly in subsets of patients with GCA. Imaging-based outcome measures should remain exploratory in future therapeutic trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2317-2327"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Journal Club 杂志俱乐部
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 DOI: 10.1002/art.70368
{"title":"Journal Club","authors":"","doi":"10.1002/art.70368","DOIUrl":"10.1002/art.70368","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149251152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification 利用机器学习和遗传风险分层从血清蛋白质组学特征中识别系统性红斑狼疮
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-27 Epub Date: 2026-05-04 DOI: 10.1002/art.70156
Mehmet Hocaoǧlu MD, Jishnu Das PhD, Amr H. Sawalha MD
{"title":"Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification","authors":"Mehmet Hocaoǧlu MD,&nbsp;Jishnu Das PhD,&nbsp;Amr H. Sawalha MD","doi":"10.1002/art.70156","DOIUrl":"10.1002/art.70156","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Proteome-wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included. Differential proteomic expressions were characterized and followed by hierarchical clustering analysis. Proteomic linear and machine learning models were developed for established disease classification and future lupus prediction and compared to polygenic risk scores. Two additional independent lupus cohorts from Sweden, as part of the Human Protein Atlas (HPA), and from China were used for replication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the UK Biobank, 44,173 participants with proteomic data, including 2,063 individuals with at least one autoimmune disease at enrollment, were studied. This included 383 patients with lupus with a mean age of 43.6 ± SD 11.7 years at disease onset. Lupus showed the largest number of dysregulated proteins among autoimmune diseases and clustered with rheumatoid arthritis. Comparison with HPA showed that ~70% of lupus proteomic associations could be replicated with moderate correlation in effect sizes. The machine learning model outperformed the linear model in identifying pre-existing lupus and generalized well to future lupus prediction. Among patients with lupus on immunomodulatory medications, the model reached ~90% sensitivity at 95% specificity, which was replicated in an independent cohort. Model interpretation highlighted SCARB2, SOD2, CD302, Galectin-9, and GGT5 proteins with substantial effects on lupus identification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Proteomic machine learning models show excellent performance for identifying pre-existing lupus and generalize well for predicting lupus before clinical diagnosis. Model interpretation identified novel candidate biomarkers for lupus.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2280-2291"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147507620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell analysis reveals CXCL16+ dendritic cells and clonally expanded GZMK+ CD4 T cells driving joint inflammation in psoriatic arthritis. 单细胞分析显示CXCL16+树突状细胞和克隆扩增的GZMK+ CD4 T细胞驱动银屑病关节炎的关节炎症。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-20 DOI: 10.1002/art.70371
Briana J Mullins, Jasmine Shwetar, Alberto Herrera, Anthony Youzhi Cheng, Katharine Lu Yang, Anthony Jiménez Hernández, Katie Tumang, Eleni P Mimitou, Ali Sahimi, Luz Alvarado, Rhina Medina, Rebecca H Haberman, Parvathy V Girija, Thomas Boehringer, Ellie Ivanova, Timothy C Borbet, Stephanie Eichman, Ian Cunningham, Kirsty Hillier, Sofia Bajwa, Celiane Cardoso Carvalho, Susan R Schwab, Mukundan G Attur, Kelly Ruggles, José U Scher, Sergei B Koralov
{"title":"Single-cell analysis reveals CXCL16<sup>+</sup> dendritic cells and clonally expanded GZMK<sup>+</sup> CD4 T cells driving joint inflammation in psoriatic arthritis.","authors":"Briana J Mullins, Jasmine Shwetar, Alberto Herrera, Anthony Youzhi Cheng, Katharine Lu Yang, Anthony Jiménez Hernández, Katie Tumang, Eleni P Mimitou, Ali Sahimi, Luz Alvarado, Rhina Medina, Rebecca H Haberman, Parvathy V Girija, Thomas Boehringer, Ellie Ivanova, Timothy C Borbet, Stephanie Eichman, Ian Cunningham, Kirsty Hillier, Sofia Bajwa, Celiane Cardoso Carvalho, Susan R Schwab, Mukundan G Attur, Kelly Ruggles, José U Scher, Sergei B Koralov","doi":"10.1002/art.70371","DOIUrl":"10.1002/art.70371","url":null,"abstract":"<p><strong>Objective: </strong>Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis affecting approximately 30% of individuals with psoriasis. The mechanisms driving PsA joint inflammation remain incompletely defined.</p><p><strong>Methods: </strong>To address this gap, we performed multimodal single-cell sequencing of immune cells from matched peripheral blood and synovial fluid (SF) from 6 PsA patients, with comparisons to a rheumatoid arthritis (RA) patient and 6 healthy controls (HC).</p><p><strong>Results: </strong>SF CD4 and CD8 T cells displayed elevated expression of TOX, PDCD1, CTLA4, GZMK, CXCR3, and CXCR6, reflecting a tissue-specific activation state. CD4 T cell sub-clustering revealed clonally expanded populations enriched for GZMK and cytotoxic gene programs, suggesting antigen-driven activation. In contrast, CD8 T cell clonality showed a significant correlation with GZMK expression, however GZMK<sup>+</sup> CD8 T cells in the joint exhibited a transcriptional signature consistent with functional exhaustion. Concurrently, SF was enriched for CD141<sup>+</sup>, CD1c<sup>+</sup>, CCR7<sup>+</sup>, and SIGLEC6<sup>+</sup> dendritic cells (DCs), characterized by increased CXCL16 expression and antigen presentation pathways. Flow cytometry and ELISA in an additional 25 PsA patients and 16 HCs confirmed protein-level enrichment of key chemokines and GZMK<sup>+</sup> T cells. Cell-cell communication analysis highlighted CXCR6-CXCL16 and CXCR3-CXCL10 chemokine axes as mediators of immune cell recruitment and retention, while in vitro assays showed enhanced migration of PsA SF T cells toward a CXCL16 gradient relative to paired blood.</p><p><strong>Conclusion: </strong>Together, these findings suggest that clonally expanded GZMK<sup>+</sup> CD4 T cells in PsA are cytotoxic and antigen-responsive, contributing to joint inflammation following recruitment by CXCL16-producing dendritic cells.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书